Investigator
Mark Anthony Nelson
PRECISION EPIGENOMICS, INC. · funded by NCI
- Companies
- 2
- Grants
- 2
- Non-dilutive funding
- $1.1M
- First award
- Aug 1, 2024
Resolved onto their grants.
Federal awards on file.
Summed across those awards.
Latest Feb 1, 2025.
Companies from this work
Pre-ticker companies the crosswalk resolved onto a grant filed under this investigator. Momentum shows for the therapeutic areas your seat covers; open a dossier for the full crosswalk.
- PRECISION EPIGENOMICS, INC.61momentum
OncologyFiled/Approved
- Precision Epigenomics Inc50momentum
OncologyFormed
Grant record
Federal awards filed under this investigator name, newest first. Each links to the public record where the awarding agency publishes one.
- R44
Development of a Molecular Assay to Diagnose Malignant Pleural Effusions
$70kFeb 1, 2025NCIPRECISION EPIGENOMICS, INC.NIH RePORTER · 11196648 (opens the source filing in a new tab)
- R44
Development of a Molecular Assay to Diagnose Malignant Pleural Effusions
$1.0MAug 1, 2024NCIPRECISION EPIGENOMICS, INC.NIH RePORTER · 11143911 (opens the source filing in a new tab)
This page aggregates public U.S. federal grant records filed under one investigator name and the companies Biodatica has resolved onto them. Names are shown as the awarding agency filed them; grant awards are non-dilutive federal funding, not equity or valuation. Distinct people who file under the same name would appear together here. It is informational only and not investment advice. Methodology · Data sources